“Dr. Grynspan has over ten years of extensive professional experience in the field of human cell therapy and will be a valuable addition to Pluristem’s management and R&D team,” said Mr. Aberman. “Prior to joining Pluristem, Dr. Grynspan made a major contribution to the development of cell products through all the phases of their clinical development. Her experience will greatly benefit Pluristem, as the company is progressing towards its Phase I clinical trial with PLX-PAD and broadening its products’ pipeline. Dr. Grynspan’s decision to join Pluristem strengthens the Company’s position as a major player in the cell therapy arena.”

Dr. Grynspan earned her Ph.D. in Chemistry/Biochemistry from the University of Illinois, Chicago and her post-doctoral degree from Harvard Medical School/McLean Hospital, where she worked in the areas of Multiple Sclerosis and Alzheimer's Disease. Prior to joining Pluristem, Dr. Grynspan served as Vice President of R&D of a pioneering cell therapy company in Israel, where she was instrumental in bringing its first cell therapy product to a multinational, multi-center Phase III clinical trial and participated in the development of its pipeline. Before that, Dr. Grynspan served as Senior Scientist at Intelligene Ltd., a developer of molecular biology diagnostic and therapeutic tools, and as an instructor and biochemist at Harvard Medical School. Dr. Grynspan has extensive experience in the fields of biochemistry, cell biology and molecular biology and has authored numerous scientific papers in the fields of autoimmune and degenerative diseases.

Dr. Grynspan stated: "Pluristem brings to the cell therapy market a solid and innovative technology, created by a team of first-rate professionals that will propel the company to the forefront of the cell therapy field. I am delighted to be part of this endeavor.”